Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Chronic glomerular diseases, associated with renal failure and cardiovascular morbidity, represent a major health issue. However, they remain poorly understood. Here we have reported that tightly controlled mTOR activity was crucial to maintaining glomerular podocyte function, while dysregulation of mTOR facilitated glomerular diseases. Genetic deletion of mTOR complex 1 (mTORC1) in mouse podocytes induced proteinuria and progressive glomerulosclerosis. Furthermore, simultaneous deletion of both mTORC1 and mTORC2 from mouse podocytes aggravated the glomerular lesions, revealing the importance of both mTOR complexes for podocyte homeostasis. In contrast, increased mTOR activity accompanied human diabetic nephropathy, characterized by early glomerular hypertrophy and hyperfiltration. Curtailing mTORC1 signaling in mice by genetically reducing mTORC1 copy number in podocytes prevented glomerulosclerosis and significantly ameliorated the progression of glomerular disease in diabetic nephropathy. These results demonstrate the requirement for tightly balanced mTOR activity in podocyte homeostasis and suggest that mTOR inhibition can protect podocytes and prevent progressive diabetic nephropathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gödel et al. [16] suggested that mTOR signaling plays a role in podocyte homeostasis.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“The decrease in activity of neurofibromin in NF1 might also be associated with LPG which is a glomerular disease, and contribute to the development of LPG as an additional factor.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
In the citing paper
“However, the side effects of long-term or complete mTORC1 inhibition in kidney cells have been well-recognized, such as the early onset of proteinuria caused by specific inhibition of mTORC1 activity in podocytes in mice and the disruption of kidney tubular homeostasis caused by specific inhibition of mTORC1 activity in kidney tubular cells in mice51,80.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationA global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Research works printed but not linked: 5
- Estacio, 2001, Adv Intern Med., 46, 359
- Munivenkatappa, 2010, Histol Histopathol., 25, 189
- Weening, 1987, Am J Pathol., 129, 64
- Artacho-Perula, 1993, Lab Invest., 68, 56
- Souster, 1980, J Anat., 130, 595
Cited by
Items 201–300 of 553
Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
“Briefly, these studies make use of two distinct models to show that mTORC1 overactivation in nondiabetic mice caused a glomerular disease closely resembling DN, while podocytespecific inhibition of mTORC1 activity protected mice from DN development [58, 143].”
BackgroundResultInfluentialThe role of local IL6/JAK2/STAT3 signaling in high glucose–induced podocyte hypertrophy
Jo, H. A., Kim, J., Yang, S. H., Han, S. S., Joo, K. W., Kim, Y. S., & Kim, D. K. (2016) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2016.09.003 · Cited by 48
Autophagy in kidney disease: Advances and therapeutic potential
Bhatia, D., & Choi, M. E. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.01.008 · Cited by 53
Signaling Mechanisms in the Regulation of Renal Matrix Metabolism in Diabetes
Mariappan, M. M. (2012) · Experimental Diabetes Research · doi:10.1155/2012/749812 · Cited by 50
Das, R., Xu, S., Nguyen, T. T., Quan, X., Choi, S.-K., Kim, S., Lee, E. Y., Cha, S., & Park, K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.703116 · Cited by 51
“Therefore, although TSC2-mediated mTOR activation has been documented as a mediator of diabetic nephropathy (6, 32), TSC2-independented mTOR activation may participate in diabetes and/or other different types of nephritic diseases.”
Liu, P., Yang, X. C., Hei, C., Meli, Y., Niu, J., Sun, T., & Li, P. A. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15624 · Cited by 48
Kumar, V., Wollner, C., Kurth, T., Bukowy, J., & Cowley, A. (2017) · HYPERTENSION · doi:10.1161/hypertensionaha.117.09456 · Cited by 37
Glucose Transporters in Diabetic Kidney Disease—Friends or Foes?
Wasik, A. A., & Lehtonen, S. H. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00155 · Cited by 50
“Hyperactivation of the mTORC1 signal is strongly associated with the progression of podocyte injury and proteinuria in diabetic animal models, characterized by dysregulation of nephrin and podocyte loss (39, 81).”
BackgroundQiu, W., Zhou, Y., Jiang, L., Fang, L., Chen, L., Su, W., Tan, R., Zhang, C., Han, X., & Yang, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041391 · Cited by 47
“Despite of the traditional focus of mesangial cells in deciphering molecular mechanisms of DN [27,30,31], accumulated evidence indicates that injury of terminally differentiated podocytes in the initial stage of DN will result in massive proteinuria, renal insufficiency and irreversible renal failure [8,9,13,15,32,33,…”
Effects of rapamycin on growth hormone receptor knockout mice
Fang, Y., Hill, C. M., Darcy, J., Reyes-Ordoñez, A., Arauz, E., McFadden, S., Zhang, C., Osland, J., Gao, J., Zhang, T., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717065115 · Cited by 46
“For instance, Rictor loss-offunction mutants in Caenorhabditis elegans had decreased life spans by 24–43% on a standard diet (12), muscle-specific inactivation of Rictor in mice produced glucose intolerance (13), kidney-specific knockout of Rictor reduced protection of kidneys from stress (14), and adipose-specific kn…”
BackgroundGuo, W., Qiu, W., Ao, X., Li, W., He, X., Ao, L., Hu, X., Li, Z., Zhu, M., Luo, D., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15052 · Cited by 52
“…is activated in diabetic liver, heart and kidney tissue. mTORC1 hyperactivation is a key determinant for the development of diabetic nephropathy (Godel et al., 2011; Inoki et al., 2011), diabetic cardiomyopathy and hepatic insulin resistance (Korsheninnikova et al., 2006; Volkers et al., 2014).”
BackgroundMicroRNAs in Podocyte Injury in Diabetic Nephropathy
Ishii, H., Kaneko, S., Yanai, K., Aomatsu, A., Hirai, K., Ookawara, S., Ishibashi, K., & Morishita, Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00993 · Cited by 48
The insulin receptor and the kidney
Hale, L. J., & Coward, R. J. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32835abb52 · Cited by 45
Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and mTOR/ P70S6K/4EBP1 Signaling
Jin, J., Hu, K. Q., Ye, M., Wu, D., & He, Q. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491905 · Cited by 45
Lv, L., Zhang, J., Fengqun, T., Li, X., Li, D., & Yu, X. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1640231 · Cited by 48
“mTOR inhibition can prevent progressive DN [55,56].”
Zhou, D., Zhou, M., Wang, Z., Fu, Y., Jia, M., Wang, X., Liu, M., Zhang, Y., Sun, Y., Zhou, Y., et al. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01828-3 · Cited by 46
Fu, X., Li, P., Zhang, L., Song, Y., An, Y., Zhang, A., Liu, W., Ye, C., Zhang, Y., Yue, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107357119 · Cited by 46
“…cochlear HCs, indicating a dichotomy of mTOR complex function in the pathophysiology of cochlear HCs. Systemic mTORC2 deletion results in embryonic death, whereas tissue-specific mTORC2 deletion (such as that in skeletal muscle, adipose tissue, and kidney) usually leads to a weak phenotype (48–51).”
Insulin signalling to the kidney in health and disease
Hale, L. J., & Coward, R. J. (2012) · Clinical Science · doi:10.1042/cs20120378 · Cited by 46
Jeruschke, S., Büscher, A. K., Oh, J. S., Saleem, M. A., Hoyer, P. F., Weber, S., & Nalbant, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055980 · Cited by 44
“The ubiquitously expressed serine-threonine kinase mTOR (mammalian target of rapamycin) is the catalytical subunit of two protein complexes controlling multiple aspects of podocyte function such as cell size, shape and proliferation [12].”
BackgroundZhang, H., Wang, W., Ren, L.-H., Zhao, X.-X., Wang, Z., Zhuang, D.-L., & Bai, Y.-N. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453163 · Cited by 44
Janssens, P., van Hoeve, K., Waele, L. D., Rechter, S. D., Claes, K. J., de Perre, E. V., Wissing, K. M., Bammens, B., Jansen, A., & Mekahli, D. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-4003-6 · Cited by 47
Huang, G., Zou, B., Lv, J., Li, T., Huai, G., Xiang, S., Lu, S., Luo, H., Zhang, Y., Jin, Y., et al. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2864 · Cited by 43
“Moreover, previous studies have demonstrated that the inhibition of mammalian target of rapamycin (mTOR) protects podocytes from injury and prevents DN through the regulation of autophagy (22,23).”
BackgroundSelf-citationPerspectives on the role of PTEN in diabetic nephropathy: an update
Khokhar, M., Roy, D., Modi, A., Agarwal, R. G., Yadav, D., Purohit, P., & Sharma, P. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1746735 · Cited by 44
Unraveling Diabetic Kidney Disease: The Roles of Mitochondrial Dysfunction and Immunometabolism
Narongkiatikhun, P., Choi, Y. J., Hampson, H. E., Gotzamanis, J., Zhang, G., van Raalte, D. H., de Boer, I. H., Nelson, R. G., Tommerdahl, K. L., McCown, P. J., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.019 · Cited by 45
Self-citationComparison of Glomerular and Podocyte mRNA Profiles in Streptozotocin-Induced Diabetes
Fu, J., Wei, C., Lee, K., Zhang, W., Wu, H., Chuang, P. Y., Liu, Z., & He, C. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015040421 · Cited by 42
Autophagy in renal tubular injury and repair
Lin, F. (2017) · Acta Physiologica · doi:10.1111/apha.12852 · Cited by 44
Mapping Txnip: Key connexions in progression of diabetic nephropathy
Kumar, A., & Mittal, R. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.12.008 · Cited by 43
Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway
Nie, Y., Fu, C., Zhang, H., Zhang, M., Xie, H., Tong, X., Li, Y., Hou, Z., Fan, X., & Yan, M. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-03050-y · Cited by 43
Sávio-Silva, C., Soinski-Sousa, P. E., Simplício-Filho, A., Bastos, R. M. C., Beyerstedt, S., & Rangel, É. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041546 · Cited by 44
“Therefore, autophagy downregulation has been clinically evidenced during the first stages of DKD due to HGdriven mTORC1 (mammalian target of rapamycin complex 1) induction in podocytes [54].”
BackgroundInfluentialPerspectives on ROCK2 as a Therapeutic Target for Alzheimer’s Disease
Weber, A. J., & Herskowitz, J. H. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.636017 · Cited by 44
“, 2009), or kidney (Gödel et al., 2011), brain architecture and neuron size are affected, suggesting a role for mTORC2 in CNS morphology (Angliker and Rüegg, 2013; Thomanetz et al.”
BackgroundNew players in the pathogenesis of focal segmental glomerulosclerosis
Schell, C., & Huber, T. B. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs273 · Cited by 44
“could now dissect the role of the mTOR complexes in podocyte maintenance and disease [52, 53].”
BackgroundSelf-citationAnsermet, C., Centeno, G., Bignon, Y., Ortiz, D., Pradervand, S., Garcia, A., Menin, L., Gachon, F., Yoshihara, H. A. I., & Firsov, D. (2021) · Kidney International · doi:10.1016/j.kint.2021.11.016 · Cited by 43
Denhez, B., Rousseau, M., Spino, C., Dancosst, D.-A., Dumas, M.-È., Guay, A., Lizotte, F., & Geraldes, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-78376-1 · Cited by 212
Diet-induced obesity and kidney disease – In search of a susceptible mouse model
Wicks, S. E., Nguyen, T., Breaux, C., Krüger, C., & Stadler, K. (2015) · Biochimie · doi:10.1016/j.biochi.2015.08.001 · Cited by 42
NQO1 protects obese mice through improvements in glucose and lipid metabolism
Francesco, A. D., Choi, Y., Bernier, M., Zhang, Y., Díaz‐Ruiz, A., Aon, M. A., Kalafut, K. C., Ehrlich, M. R., Murt, K. N., Ali, A., et al. (2020) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-020-00051-6 · Cited by 44
Borsting, E., Patel, S. V., Declèves, A., Lee, S. J., Rahman, Q. M., Akira, S., Satriano, J. A., Sharma, K., Vallon, V., & Cunard, R. A. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013070811 · Cited by 42
Podocytes in health and glomerular disease
Cunanan, J., Zhang, D., Peired, A. J., & Barua, M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1564847 · Cited by 43
Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus
Dande, R. R., Peev, V., Altintas, M. M., & Reiser, J. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3232848 · Cited by 39
“In various diabetic animal studies, it has been observed that there is podocyte hypertrophy (increase in the mean podocyte volume) [28, 29], cytoskeleton abnormalities [30, 31], and aberrant decrease in the density of podocytes [29, 32, 33].”
BackgroundEnergy restriction in renal protection
Wang, S., Cai, G., & Chen, X. (2018) · British Journal Of Nutrition · doi:10.1017/s0007114518002684 · Cited by 42
“The mTOR signalling pathway is associated with DN and polycystic kidney disease((91,92)).”
BackgroundA reciprocal regulation of spermidine and autophagy in podocytes maintains the filtration barrier
Liang, W., Yamahara, K., Hernando-Erhard, C., Lagies, S., Wanner, N., Liang, H., Schell, C., Kammerer, B., Huber, T. B., & Bork, T. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.016 · Cited by 39
Self-citationThe Loss of Mitochondrial Quality Control in Diabetic Kidney Disease
Dai, W., Lu, H., Chen, Y., Yang, D., Sun, L., & He, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.706832 · Cited by 40
The role of autophagy in the treatment of type II diabetes and its complications: a review
Zhao, X., Bie, L., Pang, D.-R., Li, X., Yang, L., Chen, D., Wang, Y.-R., & Gao, Y. J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1228045 · Cited by 41
“Markus Gödel et al. (87) discovered that mTORC1 was highly activated and autophagy was inhibited in renal podocytes of T2DM mice and patients.”
BackgroundNistala, R., & Whaley‐Connell, A. T. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.02.005 · Cited by 39
Mammalian target of rapamycin signaling in the podocyte
Inoki, K., & Huber, T. B. (2012) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e3283520f38 · Cited by 38
Self-citationKim, J., Wilbon, S. S., & Fornoni, A. (2021) · Kidney360 · doi:10.34067/kid.0006152020 · Cited by 40
Self-citationTransforming growth factor-beta and the glomerular filtration barrier
Ghayur, A., & Margetts, P. J. (2013) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2013.01.003 · Cited by 38
“Other pathways shown to be involved in podocyte EMT include mammalian target of rapamycin (mTOR) [68,69], glycogen synthase kinase 3 b (GSK3B) [70], b -catenin [71], integrin-linked kinase (ILK) [72], and Notch [73].”
BackgroundType 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm
Bar‐Tana, J. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09545-w · Cited by 44
Nephrotoxicity of Anti-Angiogenic Therapies
Wynsberghe, M. V., Flejeo, J., Sakhi, H., Ollero, M., Sahali, D., Izzedine, H., & Hénique, C. (2021) · Diagnostics · doi:10.3390/diagnostics11040640 · Cited by 42
Das, F., Bera, A., Ghosh‐Choudhury, N., Abboud, H. E., Kasinath, B. S., & Choudhury, G. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109608 · Cited by 40
“severe proteinuria at early stage [63].”
Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease
Liebau, M. C., & Serra, A. L. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2370-y · Cited by 41
Kim, D. K., Nam, B. Y., Li, J. J., Park, J. T., Lee, S. H., Kim, D., Kim, J. Y., Kang, H. Y., Han, S. H., Yoo, T., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2467-7 · Cited by 37
“In addition, the activation of mTOR complex 1 (mTORC1) and its downstream effectors, including eukaryotic elongation factor 4E-binding-protein-1 (4EBP1) and p70S6 kinase (p70S6K), play a pivotal role in diabetes-induced podocyte hypertrophy [9, 10].”
BackgroundMesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy
Paulini, J., Higuti, E., Bastos, R. M. C., Gomes, S. A., & Rangel, É. B. (2016) · Stem Cells International · doi:10.1155/2016/9521629 · Cited by 40
“Hence, when mTORC1 is genetically deleted in podocytes of diabetic mice, the progression of glomerular disease is attenuated [98].”
InfluentialZhang, M., Zhang, Y., Xiao, D., Zhang, J., Wang, X., Guan, F., Zhang, M., & Chen, L. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172955 · Cited by 37
Lei, J., Zhao, L., Zhang, Y., Wu, Y., & Liu, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000488231 · Cited by 36
Activation of mTORC1 in Collecting Ducts Causes Hyperkalemia
Chen, Z., Dong, H., Jia, C., Song, Q., Chen, J., Zhang, Y., Lai, P., Fan, X., Zhou, X., Liu, M., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013030225 · Cited by 35
Novel Actions of Growth Hormone in Podocytes: Implications for Diabetic Nephropathy
Mukhi, D., Nishad, R., Menon, R. K., & Pasupulati, A. K. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00102 · Cited by 36
“Inhibition of podocyte-specific mTORC1 prevents podocyte hypertrophy and progressive glomerulosclerosis during diabetes (93, 94).”
BackgroundEzzat, S. M., Abdallah, H. M. I., Yassen, N. N., Radwan, R. A., Mostafa, E. S., Salama, M. M., & Salem, M. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111948 · Cited by 37
Parietal cells—new perspectives in glomerular disease
Miesen, L., Steenbergen, E., & Smeets, B. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2600-5 · Cited by 35
“…or strength of inhibition. mTOR is an essential regulator of cell metabolism, growth, proliferation and survival, indicating that an over-strong or -long inhibition leads to an aggravation of glomerular injury instead of healing as has been described in detail for podocytes (Godel et al. 2011).”
BackgroundFan, K., Yuan, S., Zhou, M., Yu, Y., Guo, J., Fang, L., Zhou, C., Cui, P., Zhang, S., Li, R., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04671 · Cited by 37
IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes
Santamaría, B., Márquez, E., Lay, A. C., Carew, R. M., González‐Rodríguez, Á., Welsh, G. I., Ni, L., Hale, L. J., Ortíz, A., Saleem, M. A., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.09.020 · Cited by 36
“Similarly, differing roles of mTORC1 between the glomeruli and tubules in DN have also been reported [53,54].”
BackgroundCrucial genes associated with diabetic nephropathy explored by microarray analysis
Wang, Z., Wang, Z., Zhou, Z., & Ren, Y. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0343-2 · Cited by 36
“For example, the mammalian target of rapamycin (mTOR) complex 1 activation has a key role in podocyte dysfunction in diabetic mice [3, 4].”
BackgroundGarg, P. K., & Holzman, L. B. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.030 · Cited by 37
He, J., Liu, B., Du, X., Wei, Y., Kong, D., Feng, B., Guo, R., Asiamah, E. A., Griffin, M. D., Hynes, S. O., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03647-x · Cited by 35
“Overall, these findings were consistent with those of Gödel et al. [67], who reported significant upregulation of mTOR in human patients with progressive DN.”
ResultAutophagy and metabolic changes in obesity-related chronic kidney disease
Satriano, J. A., & Sharma, K. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft229 · Cited by 34
“Interestingly, deletion of Raptor (mTORC1 specific) alone also resulted in glomerular injury [68], suggesting a more complicated paradigm.”
BackgroundEnhanced insulin receptor, but not PI3K, signalling protects podocytes from ER stress
Garner, K., Betin, V. M. S., Pinto, V., Graham, M., Abgueguen, E., Barnes, M., Bedford, D. C., McArdle, C. A., & Coward, R. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-22233-9 · Cited by 34
Song, S., Qiu, D., Wang, Y., Wei, J., Wu, H., Wu, M. T., Wang, S., Zhou, X., Shi, Y., & Duan, H. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111862 · Cited by 36
Catar, R. A., Wischnewski, O., Chen, L., Heidecke, H., Rutz, C., Schülein, R., Dragun, D., Philippe, A., & Kusch, A. (2021) · Kidney International · doi:10.1016/j.kint.2021.09.029 · Cited by 38
Kuwagata, S., Kume, S., Chin‒Kanasaki, M., Araki, H., Araki, S., Nakazawa, J., Sugaya, T., Koya, D., Haneda, M., Maegawa, H., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.06.036 · Cited by 33
Song, S., Qiu, D., Shi, Y., Wang, S., Zhou, X., Chen, N., Wei, J., Wu, M. T., Wu, H., & Duan, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28317 · Cited by 35
“Serving as an evolutionarily conserved eukaryotic nutrient‐responsive modulator of cell survival, growth, and metabolism (Godel et al., 2011; Wullschleger, Loewith, & Hall, 2006), mTOR is a serine/ threonine protein kinase composed of the mTORC1 and mTORC2 functional complexes (Dann, Selvaraj, &…”
BackgroundMitochondrial dysfunction and NLRP3 inflammasome: key players in kidney stone formation
Su, B., Ren, Y., Yao, W., Su, Y., & He, Q. (2024) · British Journal of Urology · doi:10.1111/bju.16454 · Cited by 33
“Studies have shown that mTOR remains at low levels under normal conditions but is signi fi cantly upregulated in RTECs with acute kidney injury (AKI) [81], which in turn decreases autophagic activity [82], while increasing pro-in fl ammatory and fi brogenic cytokine expression [83,84].”
Minakawa, A., Fukuda, A., Sato, Y., Kikuchi, M., Kitamura, K., Wiggins, R. C., & Fujimoto, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-54692-z · Cited by 32
Complement factor B in high glucose–induced podocyte injury and diabetic kidney disease
Lu, Q., Hou, Q., Cao, K., Sun, X., Liang, Y., Gu, M., Xue, X., Zhao, A. Z., & Dai, C. (2021) · JCI Insight · doi:10.1172/jci.insight.147716 · Cited by 34
mTOR inhibitors and renal allograft: Yin and Yang
Zaza, G., Granata, S., Tomei, P., Masola, V., Gambaro, G., & Lupo, A. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0103-y · Cited by 32
“Numerous experimental data have shown that mTOR-I may interfere with the protein endocytosis in the tubular epithelial cells [67], podocytes homeostasis [68, 69] and VEGF secretion and activity.”
BackgroundExosomes: Biomarkers and Therapeutic Targets of Diabetic Vascular Complications
Chen, A., Wang, H., Su, Y., Zhang, C., Qiu, Y., Zhou, Y., Wan, Y., Hu, B., & Li, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.720466 · Cited by 37
Hinden, L., Ahmad, M., Hamad, S., Nemirovski, A., Szanda, G., Glasmacher, S., Kogot‐Levin, A., Abramovitch, R., Thorens, B., Gertsch, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29124-8 · Cited by 32
Podocytes … What’s Under Yours? (Podocytes and Foot Processes and How They Change in Nephropathy)
Neal, C. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00009 · Cited by 38
“These results demonstrate the requirement for tightly balanced mTOR activity in podocyte homeostasis and suggest that mTOR inhibition can protect podocytes and prevent progressive diabetic nephropathy (89).”
Jakubek, P., Pakula, B., Rossmeisl, M., Pinton, P., Rimessi, A., & Wieckowski, M. R. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03700-w · Cited by 33
“Persistent hyperglycemia contributes to mTORC1 activation, which disrupts autophagosome formation in podocytes of mice and patients with T2D, resulting in exacerbated proteinuria [70].”
BackgroundLi, F., Yuan, Y., Guo, C.-R., Cui, L.-L., Ruan, S.-X., Zhang, C.-F., Yang, Z., & Ji, D. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s96435 · Cited by 36
“13 Currently, chemically synthesized drugs, with many side effects, are clinically used for DN treatment.”
Lipid mediators of insulin signaling in diabetic kidney disease
Mitrofanova, A. V., Sosa, M. A., & Fornoni, A. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00379.2019 · Cited by 32
Self-citationMaity, S., Das, F., Kasinath, B. S., Ghosh‐Choudhury, N., & Choudhury, G. G. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014994 · Cited by 30
“13) Recently, we and others have shown that mTORC1 controls renal cell pathology in rodent models of fibrosis where TGFβ plays important role (70-76).”
BackgroundPodocyte directed therapy of nephrotic syndrome—can we bring the inside out?
Müller‐Deile, J., & Schiffer, M. (2015) · Pediatric Nephrology · doi:10.1007/s00467-015-3116-4 · Cited by 31
Motrapu, M., Świderska, M. K., Aranda, I. M., Marschner, J. A., Lei, Y., Valenzuela, L. M., Fu, J., Lee, K., Angelotti, M. L., Antonelli, G., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019070703 · Cited by 30
Das, R., Kim, S., Nguyen, N. T., Kwon, H. J., Cha, S., & Park, K. (2019) · Kidney International · doi:10.1016/j.kint.2019.05.006 · Cited by 30
Podocyte Lysosome Dysfunction in Chronic Glomerular Diseases
Li, G., Kidd, J. M., & Li, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051559 · Cited by 32
“Furthermore, genetically reducing mTOR levels by eliminating the Raptor allele dramatically prevents podocyte injury and ameliorates the progression of glomerular dysfunction during diabetes [54].”
BackgroundThe Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Oe, Y., & Vallon, V. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020032 · Cited by 34
“In the diabetic kidney, hyper-activation of mTORc1 is involved in podocyte and tubular injury [112,113].”
BackgroundHamatani, H., Hiromura, K., Sakairi, T., Takahashi, S., Watanabe, M., Maeshima, A., Ohse, T., Pippin, J. W., Shankland, S. J., & Nojima, Y. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00625.2013 · Cited by 30
Nonimmunologic targets of immunosuppressive agents in podocytes
Yoo, T., & Fornoni, A. (2015) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2015.03.003 · Cited by 29
Self-citationTouzot, M., Soulillou, J., & Dantal, J. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32835a4be2 · Cited by 32
Fawzy, M. S., Alsel, B. T. A., Ageeli, E. A., Alqahtani, S. A. M., Abdel‐Daim, M. M., & Toraih, E. A. (2018) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1499119 · Cited by 29
Uil, M., Hau, C. M., Ahdi, M., Mills, J. D., Kers, J., Saleem, M. A., Florquin, S., Gerdes, V. E. A., Nieuwland, R., & Roelofs, J. J. T. H. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz145 · Cited by 30
“However, inhibition or genetic deletion of mTOR has also been found to induce podocyte damage and subsequent proteinuria in kidney transplant recipients and in mice [46, 47].”
BackgroundEl-Said, Y. A. M., Sallam, N. A., Ain-Shoka, A. A., & Abdellatif, H. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01944-9 · Cited by 28
Pathogenesis of diabesity‐induced kidney disease: role of kidney nutrient sensing
Hinden, L., Kogot‐Levin, A., Tam, J., & Leibowitz, G. (2021) · FEBS Journal · doi:10.1111/febs.15790 · Cited by 30
Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications
Yang, L., Zhang, Z., Wang, D., Jiang, Y., & Liu, Y. (2022) · Current Drug Targets · doi:10.2174/1389450123666220111115528 · Cited by 29
McNicholas, B., Eng, D. G., Lichtnekert, J., Rabinowitz, P. S., Pippin, J. W., & Shankland, S. J. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00196.2016 · Cited by 27
Xi, G., Wai, C., White, M. F., & Clemmons, D. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.758987 · Cited by 28
“hyperglycemia or insulin resistance could lead to abnormal angiogenesis or podocyte dysfunction (40-41).”
BackgroundFan, X., Chen, X., Feng, Q., Peng, K., Wu, Q., Passerini, A. G., Simon, S. I., & Sun, C. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00411.2018 · Cited by 30
“For example, compared with Raptor knockout, additional knockout of Rictor abrogated the dysfunction of podocytes in kidney (12) but not the phenotype in skeletal muscle (2).”
BackgroundMetformin ameliorates the severity of experimental Alport syndrome
Omachi, K., Kaseda, S., Yokota, T., Kamura, M., Teramoto, K., Kuwazuru, J., Kojima, H., Nohara, H., Koyama, K., Ohtsuki, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-86109-1 · Cited by 26
Mavroeidi, V., Petrakis, I., Stylianou, K., Katsarou, T., Giannakakis, K., Perakis, K., Vardaki, E. A., Stratigis, S., Ganotakis, E. S., Papavasiliou, S. S., et al. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413482925 · Cited by 26
“mTOR activation within podocytes exerts deleterious effects in streptozotocininduced diabetes in mice, and specific inhibition of podocytic mTORC1 prevents the progression of diabetic nephropathy (Gödel et al. 2011).”
BackgroundInfluentialKitada, M., Ogura, Y., Suzuki, T., Monno, I., Kanasaki, K., Watanabe, A., & Koya, D. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0255-1 · Cited by 28
“Additionally, numerous reports including ours have shown that mTORC1 is activated in diabetic renal cells [19, 20], a process that is closely implicated in the impairment of autophagy [16].”
BackgroundAutophagy Intertwines with Different Diseases—Recent Strategies for Therapeutic Approaches
Ramesh, J., Ronsard, L., Gao, A., & Venugopal, B. (2019) · Diseases · doi:10.3390/diseases7010015 · Cited by 26
“In both types of diabetes, enhanced mTORC1 and rapamycin were reported to stop the progression of DN [115,116].”
Background
Metadata
- Authors
- Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., Wiech, T., Fornoni, A., Nelson, R. G., Kretzler, M., Wanke, R., Pavenstädt, H., Kerjaschki, D., Cohen, C. D., Hall, M. N., Rüegg, M. A., Inoki, K., Walz, G., & Huber, T. B.
- Affiliations
- University of Freiburg (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Zurich (CH)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) (DE)
- University of Miami (US)
- National Institutes of Health (US)
- University of Münster (DE)
- Medical University of Vienna (AT)
- University of Basel (CH)
- Life Sciences Institute (SG)
- Corresponding author
- Huber, Tobias B.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2197-2209
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104746
- OpenAlex
- W2051719011
- Cited by
- 547
- References
- 62
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 28 · 2023: 36 · 2022: 30 · 2021: 43 · 2020: 50 · 2019: 39 · 2018: 40 · 2017: 34 · 2016: 38 · 2015: 36 · 2014: 40 · 2013: 47 · 2012: 25
- FWCI
- 31.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (122439)
- National Institutes of Health (5r01dk083491-09)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, P30DK081943, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- mTOR, mTORC1, mTORC2, podocytes, diabetic nephropathy, glomerulosclerosis, proteinuria, glomerular hypertrophy, hyperfiltration, mTOR inhibition, glomerular disease, gene deletion
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Rapamycin-Insensitive Companion of mTOR Protein, Adult, Animals, Carrier Proteins, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Humans, Kidney Glomerulus, Mice, Inbred C57BL, Mice, Inbred ICR, Mice, Transgenic, Nephrosis, Lipoid, Proteins, Proteinuria, Transcription Factors, Trans-Activators, Mice, Knockout, Disease Progression, Gene Dosage, Genetic Predisposition to Disease, Sirolimus, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.